Author: Ravi Shankar

Aspo Plc Stock Exchange Release October 21, 2026 at 15.00 EET

Invitation to the Extraordinary General Meeting of Aspo

The shareholders of Aspo Plc (the “Company” or “Aspo“) are invited to attend the Extraordinary General Meeting to be held on Monday, 7 December 2026, at 2.00 p.m. (Finnish time) at Finlandia Hall, Helsinki Hall at the address Mannerheimintie 13e, 00100 Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at the meeting venue at 1.00 p.m. (Finnish time).

Shareholders may also exercise their voting rights by voting in advance. Instructions for advance voting are presented in this invitation under section C.

The Extraordinary General Meeting can be followed via a webcast on the website at www.aspo.com/egm-2026. It is not possible to ask questions, make counterproposals, otherwise address the meeting, or vote via webcast, and following the meeting via webcast is not considered participation in the Extraordinary General Meeting or exercise of the shareholder rights.

1. Matters on the agenda of the Extraordinary General Meeting

1                             Opening of the meeting

2                             Calling the meeting to order

3                             Election of persons to confirm the minutes and to supervise the counting of votes

4                             Recording the legality of the meeting

5                             Recording the attendance at the meeting and adopting the list of votes

6                             Approval of the Demerger Plan and resolving on the partial Demerger

The Board of Directors of Aspo proposes to the Extraordinary General Meeting that the General Meeting resolves on the partial demerger of Aspo in accordance with the demerger plan signed by the Board of Directors on 3 August 2026 (the “Demerger Plan“) and approves the Demerger Plan. As part of the demerger resolution, the Extraordinary General Meeting shall resolve as a whole on the matters presented below conditional upon the completion of the demerger. The resolution on the approval of the Demerger Plan and on the partial demerger shall be made by a qualified majority of two-thirds (2/3) of the votes cast and the shares represented at the Extraordinary General Meeting. The Demerger Plan is available on the Company’s website at www.aspo.com/egm-2026.

Pursuant to the Demerger Plan, Aspo will demerge through a partial demerger so that all of Aspo’s shares in ESL Shipping Ltd (a subsidiary of Aspo) and related assets and liabilities will transfer without a liquidation procedure to ESL Shipping Group Plc (“ESL Shipping Group“), a company to be incorporated in the demerger (the “Demerger“).

In connection with the Demerger, the Company is proposed to be re-named Telko Group Plc.

The purpose of the Demerger is to implement the divestment of the shipping business carried out by ESL Shipping Ltd and its direct and indirect subsidiaries and related assets and liabilities from Aspo in order to form a new independent group of companies, with ESL Shipping Group as the parent company. The planned date of registration of the completion of the Demerger (the “Effective Date“) is 31 December 2026. The actual Effective Date may change from the aforesaid date, as set forth in Section 17 of the Demerger Plan.

Despite the resolution of the Extraordinary General Meeting, the Board of Directors of Aspo may, at any time prior to the completion of the Demerger, resolve not to complete the Demerger if, in the view of the Board of Directors of Aspo, there exist grounds due to which such non-completion would be justified.

In accordance with the Demerger Plan, the shareholders of Aspo shall receive as demerger consideration one (1) new share in ESL Shipping Group for each share owned in Aspo (the “Demerger Consideration“), i.e., the Demerger Consideration shall be issued to the shareholders of Aspo in proportion to their shareholdings with a ratio of 1:1. The Demerger Consideration shall be issued to the shareholders of Aspo on the Effective Date, or as soon as possible thereafter in accordance with the Demerger Plan. The Demerger Consideration shall be issued through the book-entry securities system maintained by Euroclear Nordics Ltd and will be distributed automatically, meaning that no action is required from the shareholders of Aspo in relation thereto. The allocation of the Demerger Consideration is in principle based on the shareholding in Aspo on the registration day (as defined in Euroclear Nordics Ltd’s rules in force at that time) immediately preceding the Effective Date, unless the Board of Directors of Aspo resolves otherwise.

Following the completion of the Demerger on the Effective Date or promptly thereafter, ESL Shipping Group shall carry out a share-for-share exchange with the minority shareholder of ESL Shipping Ltd whereby the minority shareholder transfers its shares in ESL Shipping Ltd to ESL Shipping Group in exchange for new shares issued by ESL Shipping Group (the “Share Exchange“). A maximum of 9,250,829 new shares shall be issued, and the final number of the shares to be issued shall correspond to approximately 21.4 per cent of the shares in ESL Shipping Group not held by it or its subsidiaries following the completion of the Share Exchange. Upon the Share Exchange, ESL Shipping Ltd shall become a wholly owned subsidiary of ESL Shipping Group.

ESL Shipping Group intends to apply for admitting its shares for trading on the official list of Nasdaq Helsinki Ltd (“Nasdaq Helsinki“). Trading in the shares of ESL Shipping Group on Nasdaq Helsinki is expected to begin on or about 4 January 2027 or as soon as possible thereafter.

As part of the resolution on the Demerger, the Extraordinary General Meeting shall decide on the following matters, conditional upon the completion of the Demerger:

1. The incorporation of ESL Shipping Group and approval of its Articles of Association

ESL Shipping Group will be incorporated in connection with the registration of the completion of the Demerger on the Effective Date. It has been proposed that the company name be ESL Shipping Group Oyj (in English: ESL Shipping Group Plc). The proposed Articles of Association of ESL Shipping Group are included in full as Appendix 1 to the Demerger Plan.

2. The number of members of the Board of Directors, election of the members of the Board of Directors and the auditor of ESL Shipping Group as well as their remuneration

According to the proposed Articles of Association of ESL Shipping Group, the Board of Directors of ESL Shipping Group shall comprise a minimum of four (4) and a maximum of eight (8) members.

The Board of Directors of the Company proposes that the number of members of the Board of Directors of ESL Shipping Group shall be four (4).

The Board of Directors of the Company proposes that Rolf Jansson be elected as Chair of the Board of Directors, and that Mikael Laine, Andreas Remmer and Kaarina Ståhlberg be elected as members of the Board of Directors of ESL Shipping Group. All candidates have given their consent to the election. The Board of Directors may elect a Vice Chair from among its members.

The term of the members of the Board of Directors shall commence on the Effective Date and shall expire at the end of the first Annual General Meeting of ESL Shipping Group following the Effective Date.

All proposed members of the Board of Directors will be independent from ESL Shipping Group and its significant shareholders, excluding Rolf Jansson and Mikael Laine, who have been determined to be independent of the major shareholders of ESL Shipping Group but not independent of ESL Shipping Group under the Finnish Corporate Governance Code 2026. Rolf Jansson currently acts as the CEO of Aspo. Mikael Laine has been assessed not to be independent of ESL Shipping Group based on an overall evaluation, taking into account that he has been a member of the Board of Directors of Aspo for a period of more than ten (10) consecutive years.

The proposed composition of the Board of Directors departs from Recommendation 10 of the Corporate Governance Code, according to which the majority of the members of the Board of Directors shall be independent of the company. This is due to the fact that five (5) members were originally planned to be proposed to the Board of Directors of ESL Shipping Group. However, at the end of the selection process one of the planned candidates was prevented from participating in the Board of Directors, and thus it is proposed that four (4) members be elected.

CVs and independence assessments of all persons proposed as members of the Board of Directors of ESL Shipping Group will be made available on Aspo’s website prior to the Extraordinary General Meeting.

On the recommendation of the Shareholders’ Nomination Board of the Company, the Board of Directors of the Company proposes that each member of the Board of Directors of ESL Shipping Group be paid a monthly fee, from the later of 1 January 2027 or the Effective Date, until the close of the first Annual General Meeting of ESL Shipping Group following the Effective Date, as follows:

• Members of the Board of Directors: EUR 3,000 per month
• Chair of the Board of Directors: EUR 6,000 per month

In addition to the monthly fees, from the later of 1 January 2027 or the Effective Date onwards, it is proposed that the members of the Board of Directors of ESL Shipping Group be paid a meeting fee for each meeting of any potential Board committee, as follows: a meeting fee of EUR 1,200 per meeting to the Chair of the committee and a meeting fee of EUR 500 per meeting to each member of the committee, or EUR 1,000 per meeting for each member of the committee in case the member travels to the meeting outside their country of residence.

According to the proposed Articles of Association of ESL Shipping Group, ESL Shipping Group shall have one (1) auditor which must be an auditing firm authorized by the Finnish Patent and Registration Office.

The Board of Directors of the Company proposes that Deloitte Oy be elected as the auditor of ESL Shipping Group. Deloitte Oy has given notice that Aleksi Martamo will act as the principally responsible auditor, conditional upon the completion of the Demerger.

The Board of Directors of the Company proposes that the auditor of ESL Shipping Group be paid a fee pursuant to an invoice approved by ESL Shipping Group, conditional upon the completion of the Demerger.

3. Establishment of a Shareholders’ Nomination Board for ESL Shipping Group

The Board of Directors of the Company proposes that a Shareholders’ Nomination Board be established for ESL Shipping Group and that its charter be adopted.

The duty of the Shareholders’ Nomination Board is, among other things, to prepare proposals regarding the number and election of the members of the Board of Directors of ESL Shipping Group and remuneration of the members of the Board of Directors and potential committees of the Board of Directors to the Annual General Meeting of ESL Shipping Group.

The composition, tasks and activities of the Shareholders’ Nomination Board of ESL Shipping Group are defined in more detail in its proposed Charter that is available on Aspo’s website at www.aspo.com/egm-2026.

Notwithstanding the proposed charter, the Shareholders’ Nomination Board shall upon its establishment comprise members nominated by the four (4) largest shareholders of ESL Shipping Group, based on shareholdings of ESL Shipping Group as at the date falling one (1) month after the Effective Date (the “First Nomination Date“). In case the Effective Date occurs after 31 December 2026, the First Nomination Date shall be determined as prescribed in the Demerger Plan.

Notwithstanding the proposed charter of the Shareholders’ Nomination Board of ESL Shipping Group, the Shareholders’ Nomination Board formed in accordance with the First Nomination Date shall submit its proposals to the Annual General Meeting of ESL Shipping Group for the year 2027 no later than 1 March 2027. If the Effective Date is after 31 December 2026, the Board of Directors of ESL Shipping Group is authorized to resolve on the deadline for submitting the proposals.

4. Adoption of a remuneration policy for governing bodies of ESL Shipping Group

The Board of Directors of the Company proposes that the Extraordinary General Meeting adopts the Remuneration Policy for governing bodies of ESL Shipping Group. The resolution is an advisory resolution.

The Remuneration Policy will be available on Aspo’s website at www.aspo.com/egm-2026 no later than on 16 November 2026.

5. Authorization to decide on a share issue of treasury shares

As set out in detail in Section 16.1 of the Demerger Plan, the Board of Directors of ESL Shipping Group is proposed to be authorized to decide, following the completion of the Demerger, on a share issue of treasury shares through one or several instalments, under which an aggregate maximum of 2,500,000 shares may be conveyed, representing approximately 6.27 per cent of all shares in ESL Shipping Group, assuming that the total number of ESL Shipping Group’s shares to be issued as Demerger Consideration would be 31,338,722 shares, and taking into account the Share Exchange. The authorization is valid until the conclusion of the first Annual General Meeting held by ESL Shipping Group following the completion of the Demerger.

The authorization may be used for the financing or execution of possible corporate acquisitions or other transactions, for execution of ESL Shipping Group’s share-ownership programs or for other purposes determined by the Board of Directors of ESL Shipping Group, however, provided that as part of the share-based incentive programs, the Board of Directors of ESL Shipping Group may convey a maximum of 500,000 shares, representing approximately 1.25 per cent of all shares in the ESL Shipping Group, assuming that the total number of ESL Shipping Group’s shares to be issued as Demerger Consideration would be 31,338,722 shares, and taking into account the Share Exchange.

The authorization includes the right of the Board of Directors of ESL Shipping Group to decide on all the terms and conditions of the conveyance and thus also includes the right to convey shares otherwise than in proportion to the share ownership of the shareholders, in deviation from the shareholders’ pre-emptive right, if a compelling financial reason exists for ESL Shipping Group to do so.

6. Authorization to decide on a share issue of new shares

As set out in detail in Section 16.2 of the Demerger Plan, the Board of Directors of ESL Shipping Group is proposed to be authorized to decide, following the completion of the Demerger, on a share issue of new shares through one or several instalments, under which a maximum of 2,500,000 shares are offered for subscription, representing approximately 6.27 per cent of all shares in ESL Shipping Group, assuming that the total number of ESL Shipping Group’s shares to be issued as Demerger Consideration would be 31,338,722 shares, and taking into account the Share Exchange. The authorization is valid until the conclusion of the first Annual General Meeting held by ESL Shipping Group following the completion of the Demerger.

The authorization may be used for the financing or execution of possible corporate acquisitions or other transactions, for execution of ESL Shipping Group’s share-ownership programs or for other purposes determined by the Board of Directors of ESL Shipping Group, however, provided that as part of the share-based incentive programs, the Board of Directors of ESL Shipping Group may convey a maximum of 500,000 shares, representing approximately 1.25 per cent of all shares in the ESL Shipping Group, assuming that the total number of ESL Shipping Group’s shares to be issued as Demerger Consideration would be 31,338,722 shares, and taking into account the Share Exchange.

The authorization includes the right of the Board of Directors of ESL Shipping Group to decide on all the terms and conditions of the conveyance and thus also includes the right to decide on a directed share issue, in deviation from the shareholders’ pre-emptive right, if a compelling financial reason exists for ESL Shipping Group to do so.

7. Authorization to decide on a share issue

As set out in detail in Section 16.3 of the Demerger Plan, the Board of Directors of ESL Shipping Group is proposed to be authorized to issue and/or convey a maximum of 9,250,829 shares in ESL Shipping Group solely for the purpose of implementing the Share Exchange with the minority shareholder of ESL Shipping Ltd. The final number of shares to be issued in the Share Exchange shall correspond to approximately 21.4 per cent of the shares in ESL Shipping Group not held by ESL Shipping Group or its subsidiaries after the share issue. The authorization entitles the Board of Directors of ESL Shipping Group to decide on all terms and conditions of the share issue, including the right to issue shares also in a proportion other than that of the shareholders’ current shareholdings in ESL Shipping Group under the conditions provided in law. The authorization is valid until the conclusion of the first Annual General Meeting held by ESL Shipping Group following the completion of the Demerger.

8. Authorization to decide on the acquisition of ESL Shipping Group’s own shares and on the acceptance as pledge of ESL Shipping Group’s own shares

As set out in detail in Section 16.4 of the Demerger Plan, the Board of Directors of ESL Shipping Group is proposed to be authorized to decide, following the completion of the Demerger, on the acquisition of no more than 500,000 treasury shares using the unrestricted equity of ESL Shipping Group, representing approximately 1.25 per cent of all shares in ESL Shipping Group, assuming that the total number of ESL Shipping Group’s shares to be issued as Demerger Consideration would be 31,338,722 shares, and taking into account the Share Exchange. The authorization includes the right to accept treasury shares as a pledge. The shares may be repurchased at a price formed in trading on a regulated market on the date of the repurchase or otherwise at a price formed on the market. The shares may be repurchased otherwise than in proportion to the shares held by the shareholders (directed repurchase).

The authorization is valid until the conclusion of the first Annual General Meeting held by ESL Shipping Group following the completion of the Demerger, however for no longer than 18 months from the Effective Date.

7                             Amendment of the Articles of Association of the Company

The Board of Directors of the Company proposes that Articles 1 and 4 of the Articles of Association of the Company, i.e., the trade name and domicile, and the number of members of the Board of Directors of the Company be amended in connection with the Demerger. In their amended form, said provisions of the Articles of Association would read as follows:

1 § The trade name of the company is Telko Group Oyj, in English Telko Group Plc and in Swedish Telko Group Abp. The domicile of the company is Espoo.

4 § The Board of Directors shall consist of no fewer than four (4) and no more than eight (8) members. The members of the Board elect a Chair and may elect a Vice Chair from amongst themselves. The term of the Board will expire at the end of the ordinary annual shareholder’s meeting which next follows the election.

It is proposed that the Articles of Association of the Company remain unchanged in other respects. The amended Articles of Association of the Company shall enter into force in connection with the registration of the completion of the Demerger on the Effective Date.

8                             Resolution on the remuneration of the members of the Board of Directors and committees of the Company

The Shareholders’ Nomination Board proposes that, conditional upon the completion of the Demerger, from the later of 1 January 2027 or the Effective Date onwards the monthly fees to the Board members of the Company be paid as follows:

• Members of the Board of Directors: EUR 3,000 per month
• Chair of the Board of Directors: EUR 6,000 per month

The Shareholders’ Nomination Board further proposes that, conditional upon the completion of the Demerger, from the later of 1 January 2027 or the Effective Date onwards the meeting fees to members of the committees and Chairs of the committees be paid as follows: a meeting fee of EUR 1,200 per meeting to the Chair of the committee and a meeting fee of EUR 500 per meeting to each member of the committee, or EUR 1,000 per meeting for each member of the committee in case the member travels to the meeting outside their country of residence.

9                             Resolution on the number of members of the Board of Directors of the Company

The Shareholders’ Nomination Board proposes that the Board of Directors of the Company will have five (5) members, conditional upon the completion of the Demerger. Should any number of the candidates proposed by the Nomination Board not be available for election, the proposed number of Board members shall be decreased accordingly.

10                           Election of the members of the Board of Directors of the Company

The Shareholders’ Nomination Board proposes that Tapio Kolunsarka, Patricia Allam, Annika Ekman, Mikael Laine and Tatu Vehmas be elected as members of the Board of Directors of the Company for a term commencing on the later of 1 January 2027 or the Effective Date and expiring at the end of the next Annual General Meeting of the Company, conditional upon the completion of the Demerger. Further information on the proposed members of the Board of Directors is available on Aspo’s website at www.aspo.com/egm-2026.

Should any of the candidates proposed by the Nomination Board not be available for election, the remaining available candidates are proposed to be elected in accordance with the proposal by the Nomination Board.

All proposed members of the Board of Directors are independent from the Company and its significant shareholders, excluding Patricia Allam and Tatu Vehmas, who are not considered to be independent of the significant shareholders of the Company, and Mikael Laine, who is not considered to be independent of the Company. Patricia Allam and Tatu Vehmas are not independent of the significant shareholders of the Company due to their family relationships. Mikael Laine has been assessed not to be independent of the Company based on an overall evaluation, taking into account that he has been a member of the Board of Directors of the Company for a period of more than ten (10) consecutive years. All proposed members of the Board of Directors have given their consent to their appointment. The Board of Directors will elect a Chair and may elect a Vice Chair from among its members. The proposed individuals have announced to the Company that if they are elected, they will elect Tapio Kolunsarka as the Chair of the Board of Directors.

With regard to the procedure for the selection of the members of the Board of Directors, the Shareholders’ Nomination Board recommends that the shareholders give their view on the proposal as a whole at the Extraordinary General Meeting. The Shareholders’ Nomination Board has estimated that in addition to the qualifications of the individual candidates for the Board of Directors, the proposed Board of Directors as a whole provides excellent competence and experience for the Company and that the composition of the Board of Directors also meets other requirements set for a listed company by the Corporate Governance Code.

11                           Resolution on the forfeiture of the shares in the joint account and the rights carried by the shares

The Board of Directors proposes that the Extraordinary General Meeting resolve, in accordance with Chapter 3, Section 14 a, Subsection 3 of the Finnish Companies Act (624/2006, as amended), that rights to the shares entered in the Company’s joint book-entry account and the rights attached to such shares be forfeited and that the Board of Directors be authorized to take any and all measures required by such resolution. On 30 September 2026, the number of shares in the joint book-entry account was 4,464 corresponding to approximately 0.01 per cent of the total number of shares in the Company.

The forfeiture of shareholder rights would concern shares that are in the joint book-entry account of the Company. However, the forfeiture of rights shall not apply to such shares in the joint account with regard to which the registration of shareholder rights in the shareholder’s book-entry account has been requested prior to the decision of the Extraordinary General Meeting on the forfeiture of rights, provided that the shares in question are entered in the shareholder’s book-entry account no later than by 23 December 2026. The forfeiture of rights would apply to all shares in the joint account thereafter.

12                           Closing of the meeting

2. Documents of the Extraordinary General Meeting

This invitation to the Extraordinary General Meeting, containing all the decision proposals on the matters on the agenda of the meeting, is available on Aspo’s website at www.aspo.com/egm-2026. The Finnish language version of this invitation will also be sent by mail to each shareholder whose address is known to the Company.

The Demerger Plan (including the proposal for the Articles of Association of ESL Shipping Group, the proposed charter of ESL Shipping Group’s Shareholders’ Nomination Board and a preliminary presentation of the balance sheets of Aspo and ESL Shipping Group), Aspo’s annual review for the financial year ended 31 December 2025 and annual reports for the financial years ended 31 December 2024 and 2023 (including the Financial Statements, the Reports of the Board of Directors, and the Auditor’s Reports), Aspo’s half-year financial report for the period ended 30 June 2026 as well as interim reports for the periods ended 31 March 2026 and 30 September 2026, the minutes of Aspo’s Annual General Meeting held on 17 April 2026, and all other documents which according to the Finnish Companies Act shall be kept available for the shareholders, will be available on the abovementioned website as of 7 November 2026 at the latest. The Remuneration Policy of ESL Shipping Group will be available on the abovementioned website as of 16 November 2026 at the latest. This invitation and other documents mentioned above are also available at the Extraordinary General Meeting.

The Company will draw up and publish a Finnish language demerger and listing prospectus and an English language translation thereof, which will contain more detailed information on the Demerger and on ESL Shipping Group. The demerger and listing prospectus will be made available on Aspo’s website at www.aspo.com/egm-2026 prior to the Extraordinary General Meeting.

The minutes of the Extraordinary General Meeting will be available on the aforementioned website no later than 21 December 2026.

3. Instructions for the participants in the Extraordinary General Meeting

1                             Shareholder registered in the shareholders’ register

Each shareholder, who on the record date of the Extraordinary General Meeting, 25 November 2026, is registered in the Company’s shareholders’ register maintained by Euroclear Nordics Ltd, has the right to participate in the Extraordinary General Meeting. A shareholder whose shares are registered on their personal Finnish book-entry account or equity savings account is registered in the Company’s shareholders’ register. The possibility of using a proxy representative is described below.

Registration for the meeting and advance voting will begin on 22 October 2026, at 10.00 a.m. (Finnish time). A shareholder who is registered in the Company’s shareholders’ register and who wishes to participate in the Extraordinary General Meeting must register for the meeting and, if applicable, vote in advance no later than by 30 November 2026, at 4.00 p.m. (Finnish time) by which time the registration and possible advance votes must be received. The instructions for advance voting are presented below.

The registration can be done in the following ways:

1. on Aspo’s website at www.aspo.com/egm-2026

Electronic registration through the website requires strong electronic authentication of the shareholder or the shareholder’s proxy representative or legal representative with a Finnish, Swedish or Danish bank ID or mobile certificate.

2. by regular mail to Innovatics Oy, Yhtiökokous / Aspo, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland.

Shareholders registering by mail shall submit the registration form and possible advance voting form available on the Company’s website at www.aspo.com/egm-2026 or corresponding information in the message.

3. by e-mail to egm@innovatics.fi

Shareholders registering by e-mail shall submit the registration form and possible advance voting form available on the Company’s website at www.aspo.com/egm-2026 or corresponding information in the message.

In connection with the registration, a shareholder is required to provide the requested information, such as their name, date of birth or business ID, address, telephone number or e-mail address as well as the name of a possible authorized proxy representative, legal representative or assistant, the date of birth of the authorized proxy representative or legal representative and their telephone number and/or e-mail address. The personal data given to Aspo or Innovatics Oy will be used only in connection with the Extraordinary General Meeting and the processing of related necessary registrations. More information on the processing of the personal data is available in the privacy policy of Aspo’s Extraordinary General Meeting, which is available on the website at www.aspo.com/egm-2026.

A shareholder and their possible authorized proxy representative, legal representative, or assistant must be able to prove their identity and/or right of representation upon request at the Extraordinary General Meeting.

Additional information regarding registration and advance voting is available by phone during the registration period for the General Meeting from Innovatics Oy’s phone number +358 10 2818 909 on weekdays between 9 a.m. to 12 noon and between 1 p.m. to 4 p.m. (Finnish time).

2                             Holders of nominee-registered shares

A holder of nominee registered shares has the right to participate in the Extraordinary General Meeting by virtue of such shares, based on which they would be entitled to be registered in the shareholders’ register of the Company held by Euroclear Nordics Ltd on the record date of the meeting, 25 November 2026. In addition, the right to participate in the Extraordinary General Meeting requires that the shareholder, on the basis of such shares, has been temporarily registered into the shareholders’ register held by Euroclear Nordics Ltd at the latest by 2 December 2026, by 10.00 a.m. (Finnish time). For nominee registered shares, this constitutes due registration for the Extraordinary General Meeting.

A holder of nominee registered shares is advised to request well in advance the necessary instructions regarding the temporary registration in the Company’s shareholders’ register, the issuing of proxy documents and voting instructions, registration for the Extraordinary General Meeting and advance voting from his/her custodian bank. The account manager of the custodian bank shall register a holder of nominee registered shares, who wants to participate in the Extraordinary General Meeting, temporarily into the Company’s shareholders’ register at the latest by the time stated above and, if necessary, take care of advance voting on behalf of the nominee-registered shareholder prior to the expiry of the registration period for nominee-registered shareholders. Further information is also available on the Company’s website at www.aspo.com/egm-2026.

3                             Proxy representatives and powers of attorney

A shareholder may participate in the General Meeting and exercise their rights at the meeting by way of proxy representation. A proxy representative may also choose to vote in advance as described in this invitation. If the proxy representative registers electronically, the proxy representative must verify their identity in the electronic registration service with strong electronic identification, after which they can register on behalf of the shareholder they represent. The same applies to electronic advance voting.

If a shareholder participates in the Extraordinary General Meeting by means of several proxy representatives representing the shareholder with shares in different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the Extraordinary General Meeting.

The shareholder’s proxy representative must present a dated power of attorney or otherwise provide reliable evidence that they are entitled to represent the shareholder at the General Meeting. A template proxy is available on the Company’s website at www.aspo.com/egm-2026.

Any proxies are requested to be submitted primarily as an attachment in connection with the electronic registration or alternatively by mail to Innovatics Oy, Yhtiökokous / Aspo, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland or by email to egm@innovatics.fi before the end of the registration period. In addition to submitting the proxies, the shareholder or their proxy representative must ensure that they have registered for the General Meeting as described above in this invitation.

As an alternative to a traditional proxy, shareholders can use the electronic Suomi.fi proxy service to authorize a proxy representative. The proxy representative is named in the Suomi.fi service at www.suomi.fi/e-authorizations (authorization matter “Representation at the general meeting”). In the general meeting service, the proxy representative must verify their identity with strong electronic authentication when registering, after which the electronic authorization is automatically checked. Strong electronic authentication is done with bank ID or mobile certificate. More information about electronic authorization is available at www.suomi.fi/e-authorizations.

4                             Voting in advance

Shareholders with a Finnish book-entry account or equity savings account may also vote in advance on agenda items 6 to 11 of the Extraordinary General Meeting during the period between 22 October 2026, at 10.00 a.m. (Finnish time) – 30 November 2026, at 4.00 p.m. (Finnish time).

Advance voting can be done in the following ways:

1. on Aspo’s website at www.aspo.com/egm-2026

Advance voting requires that the shareholder or their legal representative or authorized proxy representative uses strong electronic authentication with bank ID or mobile certificate.

2. by submitting the advance voting form available on the Company’s website or corresponding information to Innovatics Oy by mail at the following address: Innovatics Oy, Yhtiökokous / Aspo, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland.
3. by submitting the advance voting form available on the Company’s website or corresponding information to Innovatics Oy by e-mail to egm@innovatics.fi.

The advance voting form is available on the Company’s website. A possible legal representative or authorized proxy representative of a shareholder must in connection with delivering the voting form provide a dated proxy or otherwise in a reliable manner demonstrate their right to represent the shareholder at the Extraordinary General Meeting.

Advance votes must be received before the end of the advance voting period. Submitting advance votes in this manner before the end of the registration and advance voting period is considered due registration for the General Meeting, if it contains the information required for registration mentioned in section C.1 above.

It is not possible for shareholders having voted in advance to use the right to request information, the right to request a vote or to vote on a possible counterproposal as stipulated in the Finnish Companies Act unless the shareholder participates in the Extraordinary General Meeting at the meeting venue in person or by way of proxy representation.

With respect to nominee registered shareholders, the advance voting takes place through their account manager. The account manager may vote in advance on behalf of the nominee registered shareholders represented by it in accordance with the provided voting instructions during the registration period for the nominee registered shares.

The agenda items subject to advance voting are deemed to have been presented unchanged at the general meeting. The terms related to the electronic advance voting and other instructions regarding the advance voting are available on the Company’s website at www.aspo.com/egm-2026.

5                             Other instructions and information

The Extraordinary General Meeting will be held in Finnish.

The Extraordinary General Meeting can be followed via a webcast on the website at www.aspo.com/egm-2026. It is not possible to ask questions, make counterproposals, otherwise address the meeting, or vote via webcast, and following the meeting via webcast is not considered participation in the Extraordinary General Meeting or exercise of the shareholder rights.

Pursuant to Chapter 5, Section 25 of the Finnish Companies Act, a shareholder who is present at the general meeting has the right to request information with respect to matters to be handled at the meeting.

Changes in the shareholding after the record date of the Extraordinary General Meeting do not affect the right to participate in the Extraordinary General Meeting or the number of voting rights held in the Extraordinary General Meeting.

Aspo has on the date of this invitation to the Extraordinary General Meeting, on 21 October 2026, a total of 31,419,779 shares and votes. The Company holds on the date hereof a total of 81,057 treasury shares, in respect of which voting rights cannot be exercised at the Extraordinary General Meeting.

Information about parking arrangements at Finlandia Hall is available on finlandiatalo.fi/en/finlandia-hall/location-transportation/. Aspo does not pay parking fees.

In Espoo, 21 October 2026

Aspo Plc
The Board of Directors

This document is not an offer for sale of securities. The ESL Shipping Group Plc shares referred to herein have not been, and will not be, registered under the US Securities Act of 1933, as amended, and may only be offered or sold pursuant to an exemption from the registration requirements thereof. This document shall not be published or disseminated, in whole or in part, directly or indirectly, in Australia, Canada, Hongkong, Japan, New Zealand, South Africa or Singapore or any other country where publication or dissemination would be unlawful. This document is not an offer to sell or solicitation of an offer to buy securities in any such jurisdiction where such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

For more information, please contact:
Taru Uotila, Senior Vice President, Legal and Sustainability, Aspo Plc, tel. +358 40 8622 318, taru.uotila@aspo.com

DISTRIBUTION:
Nasdaq Helsinki
Key media
www.aspo.com

^{Aspo creates value by owning and developing business operations sustainably and in the long term. Aspo’s businesses – ESL Shipping and Telko – enable future-proof, sustainable choices for customers in various industries. Established in 1929, today we are together about 650 experts on land and at sea. While the Nordic region is our core market, we serve our customers with world-class solutions in 18 countries around Europe and parts of Asia.}

^{Aspo is listed on Nasdaq Helsinki and is headquartered in Finland.}

^{Aspo – Sustainable value creation}

Attachment

• Aspo-Plc-Invitation-to-Extraordinary-General-Meeting-2026

HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) — Westlake Corporation (NYSE: WLK) will release its third quarter 2026 earnings prior to the market opening on Wednesday, November 4, 2026. The company will host a conference call at 11:00 a.m. Eastern Time (10:00 a.m. Central Time) on the same day to discuss the earnings release.

To access the conference by phone, it is necessary to pre-register at https://register-conf.media-server.com/register/BIb43f6e616a634ff28258b88359118d2b. Once registered, you will receive a phone number and unique PIN number. When you dial in, you will input the PIN number to be placed into the call.

The conference call and replay will be available via webcast at https://edge.media-server.com/mmc/p/myjybcxp and the earnings release can be obtained via the company’s Web page at https://investors.westlake.com.

About Westlake:

Celebrating 40 years of operations in 2026, Westlake is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer goods. For more information, visit Westlake’s web site at www.westlake.com.

For Further Information Contact:
Media Relations – L. Ben Ederington – 713.960.9111
Investor Relations – Jonathan Baksht – 713.960.9111

Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups

PETACH TIKVA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present an oral presentation at IDWeek 2026 on Thursday, October 22, 2026, in Washington, D.C. The presentation will focus on an exploratory pooled analysis of microbiology from SHIELD I, SHIELD II, and D-PLEX₁₀₀ phase 2 trial involving 2,185 patients, demonstrating a lower bacterial burden in breakthrough surgical-site infections (“SSIs”) and later occurrence of breakthrough SSIs in the D-PLEX₁₀₀ treatment arm compared to standard of care (“SoC”), with similar proportions of multidrug-resistant organisms between treatment groups.

The presentation, titled “D-PLEX₁₀₀ Lowers the Microbial Burden Without Selecting for Multidrug-Resistant Bacteria: Pooled Microbiology from Three Randomized Trials (N=2,185),” will be delivered by George M. Viola, M.D., M.P.H., Department of Infectious Diseases, Infection Control, and Employee Health, Division of Internal Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas. Co-authors are Nurit Tweezer-Zaks, M.D., M.B.A., and Meidan Dvir, Ph.D.

The analysis pooled a Phase 2 trial and two Phase 3 trials to examine the bacteria present in SSIs that occurred despite preventive treatment. Wound microbiology was evaluated in 134 patients (D-PLEX₁₀₀ arm n=51, SoC arm n=83) with culture-positive SSIs. Heavy bacterial growth was less frequent with D-PLEX₁₀₀ plus standard of care than with SoC alone (16% versus 27%, p=0.034) while breakthrough SSIs occurred later in the D-PLEX₁₀₀ arm compared to the SoC (median 10.0 vs 6.5 days; p<0.001). The proportions of multidrug-resistant organisms were similar between groups, and the difference in doxycycline resistance was not statistically significant.

Across the pooled study population, no statistically significant differences were observed in non-wound infections, systemic antibiotic use, or inflammation.

“Preventing surgical-site infections remains our primary objective. Part of infection prevention is understanding the microbiology of infections that occur despite prophylaxis. This matters even more as antimicrobial resistance is a first-order global health threat¹. This exploratory pooled analysis showed that compared with standard of care alone, treatment with D-PLEX₁₀₀ was associated with lower burden of bacterial growth, without evidence of increased antimicrobial resistance. Together with the later recorded onset of breakthrough SSIs, these findings suggest that D-PLEX₁₀₀ do not only demonstrate a relative risk reduction by 60% in the postoperative infection as seen in the SHIELD II trial, but also favourably impact the microbiologic characteristics and severity of infections that emerge despite treatment” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid.

Presentation Details
Presentation Title: D-PLEX₁₀₀ Lowers the Microbial Burden Without Selecting for Multidrug-Resistant Bacteria: Pooled Microbiology from Three Randomized Trials (N=2,185)
Abstract Number: LB-2201.6
Presenter: George M. Viola, M.D., M.P.H., Department of Infectious Diseases, Infection Control, and Employee Health, Division of Internal Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas
Session: Late Breaking Abstracts: Antimicrobials
Session Type: Oral Presentation
Session Date/Time: Thursday, October 22, 2026 | 10:30 a.m. – 11:45 a.m. ET
Location: Room 206, Walter E. Washington Convention Center, Washington, D.C.

The abstract will be available on www.polypid.com once the conference concludes.

About D-PLEX₁₀₀
D-PLEX₁₀₀, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (“SSIs”). Following the administration of D-PLEX₁₀₀ into the surgical site, PolyPid’s delivery technology, Kynatrix™, pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX₁₀₀ recently demonstrated positive results in the Phase 3 SHIELD II trial, achieving a statistically significant 60% (p=0.0013) relative risk reduction in SSI incidence following abdominal colorectal surgery with large incisions. D-PLEX₁₀₀ received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raises the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential implications of the exploratory pooled microbiology findings, the potential role of D-PLEX₁₀₀ in improving the prevention of surgical site infections, and its potential implications for antimicrobial resistance, as well as the Company’s ongoing regulatory review process for D-PLEX₁₀₀. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. These risks and uncertainties include, among others, that the pooled microbiology findings are exploratory; that they come from the culture-positive SSI subset; that wound-culture comparisons were not significant after multiplicity adjustment; that the presentation does not constitute a new primary efficacy result; and that the Company’s NDA remains under FDA review. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

¹ World Health Organization. Antimicrobial resistance. Fact sheet. Bacterial AMR was estimated to be associated with more than 4.7 million deaths globally in 2021. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Citing GBD 2021 Antimicrobial Resistance Collaborators. Lancet. 2024;404(10459):1199-1226.

FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

A live and archived audio webcast of the conference call will be available through the Investors section of the Company’s website at www.geron.com.

About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, announced today that it will report its financial results for the third quarter ended September 30, 2026 after the close of the U.S. financial markets on Wednesday, November 4, 2026.

The Company will host its earnings call on Wednesday, November 4, 2026 at 4:30pm ET to discuss its quarterly results and provide a business update.

The participant registration and webcast information are listed below. The earnings call will be simultaneously webcast on the Investors section of the red violet website at www.redviolet.com. Please login at least 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be required.

Please note participants must register to receive their unique dial-in number credentials. A general dial-in number will not be provided.

PARTICIPANT REGISTRATION & WEBCAST INFORMATION
WHEN: WEDNESDAY, NOVEMBER 4, 2026 at 4:30pm ET
Participant Registration: Click Here
Webcast URL: Click Here

Following the completion of the conference call, an archived webcast of the earnings call will be available on the Investors section of the red violet website at www.redviolet.com.

About red violet^®

At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers critical solutions, which empower organizations to operate with confidence. Our solutions enable the real-time identification and location of people, businesses, assets and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Our cloud-native, AI-enabled identity intelligence platform, CORE™, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. Our solutions are used today to enable frictionless commerce, enhance safety, and mitigate fraud and the related financial losses borne by society. For more information, please visit www.redviolet.com.

Company Contact:
Camilo Ramirez
Red Violet, Inc.
561-757-4500
ir@redviolet.com

Investor Relations Contact:
Steven Hooser
Three Part Advisors
214-872-2710
ir@redviolet.com

Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII in adults and impact on caregivers

STOUGHTON, Mass., Oct. 21, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that seven abstracts from its attention-deficit/hyperactivity disorder (ADHD) portfolio have been accepted for presentation at two scientific congresses this fall. The presentations span pediatric clinical studies and research examining daily functioning among adults and caregivers, reflecting Collegium’s commitment to building a broader understanding of ADHD across ages and real-life settings.

The data will be presented at the American Academy of Child and Adolescent Psychiatry (AACAP) 2026 Annual Meeting, taking place October 26–31 in Atlanta, and the Neuroscience Education Institute (NEI) Fall Congress, taking place November 5–8 in Colorado Springs.

The abstracts include Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII in pediatric populations, as well as retrospective analyses of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII from routine clinical practice in adults, and survey research with caregivers of children and adolescents. The real-world analyses are observational, and the investigators describe their findings as hypothesis-generating.

An estimated 15.5 million adults and 7 million children and adolescents in the United States have ADHD.^1,2 Published research has associated ADHD symptom severity with greater family burden, reduced family functioning, and lower quality of life among parents.³ Subsequent work indicates that when ADHD symptoms are inadequately controlled, routine aspects of the morning can create one of the most stressful parts of the day for both parents and children.⁴

“People living with ADHD, and the families who support them, need care they can count on throughout the day, so they can focus on school, work, and time with the people around them,” said Thomas Smith, M.D., Executive Vice President and Chief Medical Officer, Collegium Pharmaceutical, Inc. “The clinical studies and real-world research we’re presenting this fall help deepen the understanding of those daily needs and advance how ADHD is managed.”

Presentations

American Academy of Child and Adolescent Psychiatry (AACAP) 2026 Annual Meeting

October 26–31, 2026 | Atlanta, Georgia

• A Phase 4 Safety, Tolerability, and Efficacy Study of Serdexmethylphenidate/dexmethylphenidate in Children with Attention-Deficit/Hyperactivity Disorder Childress AC, Newcorn JH, Tashjian R, Corliss M. Friday, October 30

Neuroscience Education Institute (NEI) Fall Congress

November 5–8, 2026 | Colorado Springs, Colorado

• A Phase 4, Randomized, Double-blind Study of Serdexmethylphenidate/dexmethylphenidate in Children with Attention-Deficit/Hyperactivity Disorder Childress AC, Newcorn JH, Lewis L, Adusumilli S, Tashjian R, Corliss M.
  Friday, November 7
• A Phase 4 Safety, Tolerability, and Efficacy Study of Serdexmethylphenidate/dexmethylphenidate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder Childress AC, Newcorn JH, Lewis L, Tashjian R, Corliss M.
  Friday, November 7
• Modeling Clinical Response Patterns of AZSTARYS (SDX/d-MPH) and Other ADHD Pharmacotherapies Using Real-World Clinical Data Young J, Powell R, Powell A, Welling L, Saal J, Friedman Fechter E, Friedman H, Nash M.
  Friday, November 7
• The Association Between Delayed-Release/Extended-Release Methylphenidate Starting Dose and Treatment Persistence in Adults with ADHD Young J, Powell R, Powell A, Welling L, Friedman Fechter E, Friedman H, Saal J, Nash M.
  Friday, November 7
• Morning Functioning During Evening-Dosed Delayed-Release/Extended-Release Methylphenidate in Adults With ADHD: A Retrospective Real-World Analysis Young J, Powell R, Powell A, Welling L, Friedman Fechter E, Friedman H, Saal J, Nash M.
  Friday, November 7
• Morning Functioning and Caregiver Strain Across ADHD Medication Regimens: A Real-World Survey Study Young J, Powell R, Powell A, Welling L, Friedman Fechter E, Friedman H, Saal J, Nash M.
  Friday, November 7

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical is a dynamic biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system (CNS) and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) CII and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate) CII, and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.

For more information, please visit collegiumpharma.com or find us on LinkedIn.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: ABUSE, MISUSE, AND ADDICTION

JORNAY PM and AZSTARYS have high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including JORNAY PM and AZSTARYS, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing JORNAY PM or AZSTARYS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse and addiction.

CONTRAINDICATIONS

Known hypersensitivity to methylphenidate, serdexmethylphenidate, or other components of JORNAY PM or AZSTARYS. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate products.

Concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of a MAOI, because of the risk of hypertensive crisis.

WARNINGS AND PRECAUTIONS

Risks to Patients with Serious Cardiac Disease: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease.

Increased Blood Pressure and Heart Rate.

Psychiatric Adverse Reactions: Prior to initiating JORNAY PM or AZSTARYS, screen patients for risk factors for developing a manic episode.

Priapism: If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention.

Peripheral Vasculopathy, including Raynaud’s Phenomenon: Observe patients for digital changes during treatment.

Long-Term Suppression of Growth in Pediatric Patients: Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted.

Acute Angle Closure Glaucoma and Increased Intraocular Pressure (IOP): Patients considered at risk for acute angle closure glaucoma and IOP should be evaluated by an ophthalmologist.

Motor and Verbal Tics, and Worsening of Tourette’s Syndrome.

ADVERSE REACTIONS

Based on accumulated data from other methylphenidate products, the most common (>5% and twice the rate of placebo) adverse reactions are appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, and blood pressure increased.

Additional adverse reactions (≥5% and twice the rate of placebo) in JORNAY PM-treated pediatric patients 6 to 12 years are headache, psychomotor hyperactivity, and mood swings.

DRUG INTERACTIONS

Adjust dosage of antihypertensive drug as needed. Monitor blood pressure.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION
JORNAY PM (methylphenidate HCl) extended-release capsules and AZSTARYS (serdexmethylphenidate and dexmethylphenidate) capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older.

Limitations of Use: It is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Please click here for Full Prescribing Information for JORNAY PM and AZSTARYS, including Boxed Warning.

Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com

References

1. Staley BS, Robinson LR, Claussen AH, et al. Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023. MMWR Morb Mortal Wkly Rep. 2024;73(40):890-895.
2. Danielson ML, Claussen AH, Bitsko RH, et al. ADHD Prevalence Among U.S. Children and Adolescents in 2022: Diagnosis, Severity, Co-Occurring Disorders, and Treatment. J Clin Child Adolesc Psychol. 2024;53(3):343-360. doi:10.1080/15374416.2024.2335625
3. Peñuelas-Calvo I, Palomar-Ciria N, Porras-Segovia A, et al. Impact of ADHD symptoms on family functioning, family burden and parents’ quality of life in a hospital area in Spain. Eur J Psychiatry. 2021;35(3):166-172.
4. Sallee FR. Early Morning Functioning in Stimulant-Treated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, and its Impact on Caregivers. J Child Adolesc Psychopharmacol. 2015 Sep;25(7):558-65. doi: 10.1089/cap.2014.0160. Epub 2015 Jul 7. PMID: 26151738; PMCID: PMC4576958.

SHANGHAI, China, Oct. 21, 2026 (GLOBE NEWSWIRE) — Huachen AI Parking Management Technology Holding Co., Ltd. (NASDAQ: HCAI) (“Huachen” or the “Company”), today announced a 1-for-20 reverse stock split of the Company’s Class A ordinary shares and Class B ordinary shares (the “Reverse Stock Split”).

Beginning with the opening of trading on October 23, 2026, the Company’s Class A ordinary shares will trade on the Nasdaq Capital Market on a reverse-split-adjusted basis under the existing ticker symbol “HCAI.” The new CUSIP number of the Company’s Class A ordinary shares will be G4645R205. When the Reverse Stock Split becomes effective, every twenty (20) issued and outstanding Class A ordinary shares will be automatically combined into one (1) Class A ordinary share, and every twenty (20) issued and outstanding Class B ordinary shares will be automatically combined into one (1) Class B ordinary share.

“The reverse stock split is intended to support our efforts to maintain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2),” said Bin Lu, Chief Executive Officer of Huachen. “While the Reverse Stock Split is intended to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), the Company cannot assure that it will be able to regain or maintain compliance with Nasdaq’s continued listing standards. We remain focused on executing our strategic initiatives and enhancing long-term value for our shareholders.”

As a result of the Reverse Stock Split, the number of outstanding Class A ordinary shares of Huachen will be reduced from 10,379,942 to approximately 518,997 shares, and the number of outstanding Class B ordinary shares of Huachen will be reduced from 533,334 to 26,667 shares, subject to the rounding up of fractional shares.

Concurrently with the Reverse Stock Split, the Company amended its Memorandum and Articles of Association to proportionately reduce the number of authorized ordinary shares for issuance and change the par value of the post-Reverse Stock Split ordinary shares to $0.00075 per share. All outstanding options, warrants and other securities entitling holders to purchase or receive ordinary shares will be adjusted in accordance with their respective terms.

No fractional shares will be issued in connection with the Reverse Stock Split. Shareholders who would otherwise be entitled to receive fractional shares will receive one full share.

About Huachen AI Parking Management Technology Holding Co., Ltd.

Huachen AI Parking Management Technology Holding Co., Ltd. is a China-based, one-stop provider of smart-parking systems and precision structural parts. Through our operating subsidiaries we design, manufacture, install and service space-saving cubic parking garages—tailored to each client’s needs with technologies such as vertical lifting and multi-layer cycling—while also supplying custom steel components and railroad accessories to industrial customers nationwide.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “continue” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the Company’s most recent annual report filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For further information about Huachen, please contact:

Huachen AI Parking Management Technology Holding Co., Ltd

Alan Li: ir@huachenai.com

Mobile: +852-95791074

MILWAUKEE, Oct. 21, 2026 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN) today announced that it will release its fiscal 2027 first-quarter results at approximately 8:00 am Eastern on November 4, 2026, and host a webcast and conference call to discuss those results at 9:00 am Eastern. Following their prepared remarks, the Company will host a question-and-answer session with the investment community.

The live audio webcast will be available on Twin Disc’s website at https://ir.twindisc.com. To participate in the conference call, please dial (646) 307-1963 approximately ten minutes before the call is scheduled to begin. A replay of the webcast will be available at https://ir.twindisc.com shortly after the call until November 5, 2027.

About Twin Disc

Twin Disc, Inc. designs, manufactures, and sells marine and heavy-duty off-highway power transmission equipment. Products offered include: marine transmissions, azimuth drives, surface drives, propellers, and boat management systems, as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, control systems, and braking systems. The Company sells its products to customers primarily in the pleasure craft, commercial and military marine markets, as well as in the energy and natural resources, government, military and industrial markets. The Company’s worldwide sales to both domestic and foreign customers are transacted through a direct sales force and a distributor network. For more information, please visit www.twindisc.com.

Investors:

IMS Investor Relations

twindisc@imsinvestorrelations.com

Source: Twin Disc, Incorporated

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.

Also today, Rhythm announced participation in two upcoming investor conferences:

• David Meeker, M.D., Chairman, President and Chief Executive Officer will participate in a fireside chat at the Guggenheim 3^rd Annual Healthcare Innovation Conference on Monday, November 9 at 9:00 a.m. ET.
• Hunter Smith, Chief Financial Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11 at 11:20 a.m. ET.

Live webcasts of both the financial results conference call and the fireside chats will be available under “Events and Presentations” in the Investor Relations section of the Rhythm Pharmaceuticals website at http://ir.rhythmtx.com/. The archived webcast of the financial results conference call will be available on Rhythm’s website approximately two hours after it concludes and will be available for 30 days following the call. A replay of the fireside chats will also be available on the Rhythm website for 30 days following the presentation.

About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE^® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. The European Commission (EC) has authorized setmelanotide for the treatment of obesity and control of hunger in patients 4 years of age and above with acquired hypothalamic obesity; and both the EC and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.

Setmelanotide Indication
In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.

Limitations of Use

Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:

• Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign
• Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.

Important Safety Information

CONTRAINDICATIONS

Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

WARNINGS AND PRECAUTIONS

Disturbance in Sexual Arousal: Spontaneous penile erections and increased frequency of penile erections in males have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

Depression and Suicidal Ideation: Depression and suicidal ideation have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation occurred in the majority of IMCIVREE-treated patients. IMCIVREE may also cause development of new melanocytic nevi or darkening of pre-existing nevi. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.

Acute Adrenal Insufficiency with Acquired HO: Patients with acquired HO and secondary adrenal insufficiency reported serious adverse reactions related to acute adrenal insufficiency in 5% of IMCIVREE-treated patients and no placebo-treated patients. In patients with secondary adrenal insufficiency, monitor for clinical signs of acute adrenal insufficiency.

Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus: Patients with acquired HO and concomitant central diabetes insipidus (DI)/arginine vasopressin (AVP) deficiency reported hyponatremia in 6% of IMCIVREE-treated patients and 2% of placebo-treated patients and hypernatremia in 5% of IMCIVREE-treated patients and 4% of placebo-treated patients. Monitor serum sodium levels with changes in fluid intake and hydration status. Adjust the doses of concomitant therapies for DI/AVP deficiency as needed.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20% in at least 1 indication) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

USE IN SPECIFIC POPULATIONS

Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.

Please see the full Prescribing Information for additional Important Safety Information.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the release of our financial results and our participation in upcoming events and presentations, and the date, time and content thereof and the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the three months ended March 31, 2026, and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Corporate Contacts:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com  

Kate Walsh
Director, Corporate Communications
Rhythm Pharmaceuticals, Inc.
(857) 264-4280
kwalsh@rhythmtx.com

DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third quarter 2026 financial results and conduct a conference call on Wednesday, October 28, 2026. The Company will issue a press release detailing its third quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.

Information on how to participate is as follows.

Access to the live call:
Via telephone: Dial in within the United States: 888-506-0062 
International dial in: 973-528-0011
Access Code: 314562

Via online: A webcast of the call will be available on the Investor Relations section of the Company’s website at www.amarincorp.com.

Access to the replay:  
Via telephone: Dial in within the United States: 877-481-4010  
International dial in: 919-882-2331   
Replay Code:54490

Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company’s website at www.amarincorp.com, beginning shortly after the end of the live call and available until 4/28/27.

About Amarin
At the Heart of Amarin Corporation is a singular focus on advancing cardiovascular disease prevention worldwide. Our flagship oral prescription therapy, VASCEPA^® (icosapent ethyl or IPE), is the U.S. market leader across all available IPE products and has been prescribed more than 31 million times globally. Through our independent U.S. commercial operations and global commercial partnerships, Amarin supports access to VASCEPA/VAZKEPA^® across nearly 100 markets worldwide. For more information, visit www.amarincorp.com and follow Amarin on LinkedIn, X, Facebook. To be added to the Company’s email list and receive news directly, please visit  https://investors.amarincorp.com/email-alerts.  

Availability of Other Information About Amarin 
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information   
Media Inquiries: 
Amarin Corporation plc 
PR@amarincorp.com  

Investor Inquiries:
Devin Sullivan & Conor Rodriguez
The Equity Group on Behalf of Amarin
dsullivan@theequitygroup.com or crodriguez@theequitygroup.com
Investor.relations@amarincorp.com